Results 11 to 20 of about 41,304 (260)

Thrombocytopenia Induced by Direct Oral Anticoagulants: a Clinical Case and Literature Review

Рациональная фармакотерапия в кардиологии, 2022
The last decade has dramatically changed the strategy of anticoagulant therapy in patients with atrial fibrillation. Direct oral anticoagulants have replaced vitamin K antagonists: either direct thrombin blockers (dabigatran) or factor IIa blockers ...
B. A. Tatarsky, N. V. Kazennova
doaj   +1 more source

Sudden hemothorax as a rare initial manifestation of bronchiectasis under a direct oral anticoagulant

Surgical Case Reports, 2022
Background A hemothorax as the initial manifestation of bronchiectasis is extremely rare. We report a case of a sudden hemothorax due to exacerbation of clinically latent bronchiectasis under a direct oral anticoagulant.
Hikaru Nakayama, Asuka Uebayashi, Shota Yagi, Shuhei Iizuka, Yoshiro Otsuki, Toru Nakamura   +5 more
doaj   +1 more source

Choice of Oral Anticoagulant: Outcomes in Atrial Fibrillation Patients Post-Stroke Despite Direct Oral Anticoagulant Use

CJC Open, 2023
Background: For patients with atrial fibrillation who have an ischemic stroke or transient ischemic attack (TIA) despite taking direct oral anticoagulants (DOACs), the optimal strategy for ongoing anticoagulation is unknown.
Eric Duong, BSc, MSc, PharmD, Mu Lin, PhD, Mathew Hodgson, BSP, Glen Jickling, MD, MSc, FRCPC, Kirsten George-Phillips, BSP, Tammy J. Bungard, BSP, PharmD   +5 more
doaj   +1 more source

Safety of direct oral anticoagulants in patients with atrial fibrillation and high risk of stroke (review of literature)

Учёные записки Санкт-Петербургского государственного медицинского университета им. Акад. И.П. Павлова, 2020
Review discusses the problem of non-vitamin K antagonist oral anticoagulants safety in patients with non-valvular atrial fibrillation. Bleeding risk assessment while applying anticoagulant therapy, preventive methods for major bleeding (intracranial ...
E. I. Baranova, V. A. Ionin, A. A. Katsap, O. S. Kolesnik, E. V. Lebedeva   +4 more
doaj   +1 more source

Prevention of ischemic stroke in atrial fibrillation from the point of view of a neurologist. Standards and real clinical practice

Терапевтический архив, 2021
The article outlines aspects of the current state of the problem of the priority choice of an oral anticoagulant for indefinite prevention of stroke and systemic thromboembolism in patients with atrial fibrillation.
Marina Yu. Maksimova, Andrei V. Fonyakin, Liudmila A. Geraskina   +2 more
doaj   +1 more source

Assessing operative delay and complications in hip fracture patients on anticoagulants and antiplatelets

SAGE Open Medicine, 2023
Objectives: Hip fractures represent a prevalent geriatric cause of morbidity and mortality. The presence of multiple comorbidities requiring the use of an anticoagulant or antiplatelet medication adds complexity to management and influences outcomes ...
Asheesh R Elete, Yash Panwar, Jasan Dannaway, Jacqueline Chen, Bijoy Thomas   +4 more
doaj   +1 more source

Potential of anticoagulant therapy in cardiology practice for thrombocytopenia. Literature review

Российский кардиологический журнал, 2023
The review article discusses the issues of anticoagulant therapy in cardiovascular patients with thrombocytopenia (TP), gives the concept of ethylenediaminetetraacetic acidand heparin-induced TP.
K. G. Pereverzeva, S. S. Yakushin, A. An. Korshikova   +2 more
doaj   +1 more source

The risk of bleeding minimization with direct oral anticoagulants

Атеротромбоз, 2021
This review is devoted to the safety issues of anticoagulant therapy prescribed for the prevention of stroke and systemic embolism in patients with atrial fibrillation. Direct oral anticoagulants are considered worldwide in accordance with the guidelines
Т. N. Novikova
doaj   +1 more source

The new way of Dabigatran reversal – Idarucizumab

Journal of Education, Health and Sport, 2019
Since last few years a popularity of new oral anticoagulants significantly raised. There are following main direct oral anticoagulants (DOAC) used in therapy: Dabigatran, Rywaroxaban, Apixaban, Endoxaban.
Erwin Ciechański, Krystian Ciechański, Magda Ciechańska, Jarosław Szponar   +3 more
doaj   +3 more sources

Reversal of direct oral anticoagulants

Vascular Health and Risk Management, 2017
Reversal agents for direct oral anticoagulants (DOACs), including factor X inhibitors and direct thrombin inhibitors, are a major concern in clinical practice. After DOACs were introduced and became widely used as an alternative for vitamin K antagonists in the management of venous thromboembolism and nonvalvular atrial fibrillation, the need for ...
X-Y, Zhang, M J, Desborough, S, Shapiro
openaire   +7 more sources